
We are no longer providing equity research on Tongjitang Chinese Medicines Company TCM . We provide broad coverage of more than 1 , 800 companies , and we adjust our coverage as necessary based on client demand and investor interest .
estimate intact after learning that Tongjitang Chinese Medicines TCM acquired a fellow provider of traditional Chinese medicine. Tongjitang bought privately held Anhui Jingfang ..... Gutong and Jingshu will further bolster Tongjitang 's reputation as an orthopedic-specialty
fair value estimate after reviewing Tongjitang Chinese Medicines' TCM year-end results. Fourth-quarter ..... has remained fairly stable, and Tongjitang 's gross margin stayed relatively flat ..... Life Pharmaceutical business, although Tongjitang was able to keep other operating expenses
With Tongjitang Chinese Medicines' TCM year-end results due next month ..... the firm, will depend largely on Tongjitang 's ability to stem counterfeiting ..... in XLGB--will be central to Tongjitang 's profitability in 2008. If
We are putting Tongjitang Chinese Medicines TCM under review while we review our underlying assumptions and transfer coverage to a new analyst. We will publish a new report shortly.
Tongjitang Chinese Medicines' TCM second-quarter results were disappointing ..... hurt by the counterfeits. Although Tongjitang has filed a lawsuit against the ..... ago period. More bad news for Tongjitang was the resignation of its CFO
Tongjitang Chinese Medicines TCM announced last Friday that its chairman ..... we believe it is prudent to value Tongjitang at a stand-alone basis, and we ..... the firm's results. Sales of Tongjitang 's flagship product Xianling Gubao
Tongjitang Chinese Medicines TCM recently received a privatization ..... as we think the likelihood that Tongjitang 's board of directors accepting ..... since its initial public offering. Tongjitang also recently announced that it